Tempus AI Stock (TEM) Opinions on Analyst Coverage Initiation

By: Quiver DiscussionTracker

Posted: 39 minutes ago / June 3, 2026 5:33 p.m. UTC

Wolfe Research initiates: Social media participants noted Wolfe Research’s new coverage of Tempus AI with a Peerperform rating, highlighting the company’s strong position in therapy selection while flagging uncertainties around its MRD asset and data monetization potential.

Data moat emphasized: Observers highlighted the firm’s proprietary multimodal data advantage exceeding 500 petabytes in clinico-genomic and imaging resources, with several pointing to aligned technicals and fundamentals as factors that could support a market repricing over time.

Short interest and risks: Discussions also touched on the 20% short interest and references to prior market predecessors, with some expressing caution about business model viability despite momentum from high-profile backers.

Note: This discussion summary was generated from an AI condensation of post data.

Tempus AI Insider Trading Activity

Tempus AI insiders have traded $TEM stock on the open market 56 times in the past 6 months. Of those trades, 0 have been purchases and 56 have been sales.

Here’s a breakdown of recent trading of $TEM stock by insiders over the last 6 months:

• ERIC P LEFKOFSKY (CEO and Chairman) has made 0 purchases and 36 sales selling 1,033,422 shares for an estimated $57,086,991.
• JAMES WILLIAM ROGERS (Chief Financial Officer) has made 0 purchases and 5 sales selling 40,903 shares for an estimated $2,535,231.
• ANDREW POLOVIN (EVP, Chief Legal Officer) has made 0 purchases and 4 sales selling 27,795 shares for an estimated $1,524,677.
• RYAN FUKUSHIMA (CEO, Data) has made 0 purchases and 3 sales selling 28,142 shares for an estimated $1,484,856.
• ERIK PHELPS (EVP, Chief Admin. Officer) has made 0 purchases and 3 sales selling 10,766 shares for an estimated $650,253.
• RYAN M BARTOLUCCI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 7,018 shares for an estimated $352,755.
• WAYNE A.I. FREDERICK sold 3,675 shares for an estimated $283,820
• THOMAS EDWARD SCHOENHERR (CEO, Diagnostics) sold 1,580 shares for an estimated $69,630
• DAVID R EPSTEIN sold 370 shares for an estimated $21,981

To track insider transactions, check out Quiver Quantitative’s insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

Tempus AI Revenue

Tempus AI had revenues of $348.1M in Q1 2026. This is an increase of 36.12% from the same period in the prior year.

You can track TEM financials on Quiver Quantitative’s TEM stock page.

You can access data on TEM stock through the Quiver Quantitative API.

Tempus AI Congressional Stock Trading

Members of Congress have traded $TEM stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $TEM stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative’s congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

Tempus AI Hedge Fund Activity

We have seen 253 institutional investors add shares of Tempus AI stock to their portfolio, and 263 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• UBS GROUP AG added 1,750,525 shares (+118.0%) to their portfolio in Q1 2026, for an estimated $79,158,740
• BLACKROCK, INC. added 1,452,220 shares (+19.3%) to their portfolio in Q1 2026, for an estimated $65,669,388
• BAILLIE GIFFORD & CO removed 950,999 shares (-9.8%) from their portfolio in Q4 2025, for an estimated $56,156,490
• D. E. SHAW & CO., INC. removed 847,169 shares (-41.8%) from their portfolio in Q4 2025, for an estimated $50,025,329
• SUMITOMO MITSUI TRUST GROUP, INC. added 821,490 shares (+23.4%) to their portfolio in Q1 2026, for an estimated $37,147,777
• AMOVA ASSET MANAGEMENT AMERICAS, INC. added 821,490 shares (+23.4%) to their portfolio in Q1 2026, for an estimated $37,147,777
• VANGUARD GROUP INC added 817,014 shares (+8.7%) to their portfolio in Q4 2025, for an estimated $48,244,676

To track hedge funds’ stock portfolios, check out Quiver Quantitative’s institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Tempus AI Government Contracts

We have seen $20,963,166 of award payments to $TEM over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

To track government contracts to publicy traded companies, check out Quiver Quantitative’s government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

Tempus AI Analyst Ratings

Wall Street analysts have issued reports on $TEM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

• Canaccord Genuity issued a “Buy” rating on 12/22/2025

To track analyst ratings and price targets for Tempus AI, check out Quiver Quantitative’s $TEM forecast page.

Tempus AI Price Targets

Multiple analysts have issued price targets for $TEM recently. We have seen 11 analysts offer price targets for $TEM in the last 6 months, with a median target of $68.0.

Here are some recent targets:

• Ryan MacDonald from Needham set a target price of $75.0 on 06/01/2026
• Mark Massaro from BTIG set a target price of $80.0 on 06/01/2026
• Yi Chen from HC Wainwright & Co. set a target price of $64.0 on 05/11/2026
• Dan Brennan from TD Cowen set a target price of $68.0 on 05/06/2026
• Tycho Peterson from Jefferies set a target price of $35.0 on 04/13/2026
• Subbu Nambi from Guggenheim set a target price of $60.0 on 03/30/2026
• Tejas Savant from Morgan Stanley set a target price of $70.0 on 03/03/2026

This article is not financial advice. See Quiver Quantitative’s disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.